AstraZeneca is throwing one last Hail Mary following a string of Big Pharma defeats challenging the legality of the Inflation ...

Under an expanded agreement with its customer argenx SE, a Belgian biopharmaceutical company, FUJIFILM will produce a drug ...

Lower eGFRs were associated with higher likelihood of developing kidney failure and death among adults with diabetes, ...

Pfizer enters the obesity drug market with its Metsera acquisition, aiming to challenge leaders Eli Lilly and Novo Nordisk.

Bagsværd, Denmark Saturday, September 20, 2025, 11:00 Hrs [IST] ...

FOR many, fat jabs have done a world of good – dulling hunger pangs and banishing maddening “food noise”, causing pounds to ...

NVO gains ground in the GLP-1 battle as Ozempic outshines Trulicity in heart risk reduction and Rybelsus wins EU approval for ...

The WHO has added GLP-1 agonists to its Essential Medicines List in 2025. Learn more about the impact of this decision.

Michael Langer, son of Bob Langer, raised $78 million for T.Rx Capita l, his new venture capital fund. Dualitas Therapeutics raised $65 million in a Series A financing round. AllRock Bio announced a ...

Lilly’s cardiovascular outcomes trial is the first to use an active comparator, finding noninferiority but not superiority of tirzepatide to dulaglutide in CV outcomes.

Since 2023, GLP-1 drugs have fueled blockbuster sales: Novo Nordisk’s semaglutide earned $16.35B (weight-loss sales up 78%), and Eli Lilly’s tirzepatide $14.73B (weight-loss sales up 223%) in the ...

Denmark: Novo Nordisk has announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use ...